Home / Dividend Stocks (page 60)

Dividend Stocks

Hopefully a new story in 2020 for AltaGas…

ALA-AltaGas.png

AltaGas is a North American diversified energy infrastructure company. It engages in delivering affordable natural gas through regulated distribution utilities and transacts more than 1.5 Bcf/d of natural gas. In addition, AltaGas provides storage facilities, interstate natural gas transportation, energy efficiency contracting and retail power marketing services. The company operates ...

Read More »

Dividend Kings versus the S&P 500 Index…

Dividend-Kings.png

There are investors like me who believe that investing in companies with consistently growing dividends will lead to good performance. Collectively, we are known as Dividend Growth Investors or ‘DGI’ for short. But there are others who argue that investing in an index fund or index ETF such as the ...

Read More »

A Pure-Play Office REIT…

SOT.UN-Slate-Office-REIT.png

Slate Office REIT is a pure-play North American office REIT. It is an open-ended real estate investment trust. Its asset portfolio consists of high-quality downtown and suburban office properties with a diversified footprint, comprising of 39 properties (36 office properties and 3 non-office properties) spanning 7.5 million square feet. These ...

Read More »

Dividend Income – November 2019…

Dividend-Income-November-2019-1.png

The banks are finally seeing some resistance in their business. Many of the top Canadian banks did not report good earnings and that’s just the way it goes. Is it panic time? Not at all. Could be an opportunity to buy more but if you are having difficulty with the ...

Read More »

A Stable High Yield For This REIT…

HR.UN-HR-Reit.png

H&R REIT is one of Canada’s largest fully internalized diversified real estate investment trusts. It has interests in an asset portfolio comprising of office, retail, industrial and residential properties spanning across 41 million square feet in North America. As one of Canada’s largest REITs, H&R has assets worth $14.3 billion. ...

Read More »

A Struggling Pharmacy – Is it the tipping point?…

CVS-CVS-Health.png

CVS Health Corp. is a leading healthcare innovation company. It is the largest integrated pharmacy health care provider in the U.S. The company provides integrated offerings across the entire spectrum of pharmacy care. CVS Health operates through 10,000 retail locations in 49 states, the District of Columbia and Puerto Rico. ...

Read More »

Medtronic – A strong player in the medical devices industry…

MDT-Medtronic.png

Medtronic, Inc. is a leading medical device company in the world. It ranks among the world’s largest medical technology, services, and solutions companies. The company has a leadership position in therapeutic and diagnostic medical markets worldwide. Medtronic operates through the following segments – Cardiac & Vascular (38% of 2018 revenue), ...

Read More »

Pfizer – An opportunity or a falling knife?…

PFE-Pfizer.png

Pfizer is a global biopharmaceutical giant engaged in the manufacture and development of healthcare products. It is one of the largest global pharmaceutical companies with more than $50 billion in revenues. The company has a presence across major therapeutic areas including Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare ...

Read More »

A Solid Pharma with a Diversified Pipeline…

MRK-Merck.png

Merck & Co. is a global innovative healthcare company with a rich history of 125 years. The company provides a wide range of prescription medicines, vaccines, biologic therapies, and animal health products.The company’s operations are managed through four segments, Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The Pharmaceutical (~90% ...

Read More »

A solid acquisition for a strong drug pipeline…

BMY-Bristol-Myers-Squibb.png

Bristol Myers Squibb is a global specialty biopharmaceutical company. It focuses on diseases such as oncology, cardiovascular, immunoscience and fibrosis. The company’s planned acquisition of Celgene should further position it as a leading biopharmaceutical company, expanding its oncology and immunoscience portfolios. About 56% of Bristol Myers’ 2018 revenues were derived ...

Read More »
NFL Jerseys 2019